US5376645A
(en)
*
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
US5262404A
(en)
*
|
1990-02-15 |
1993-11-16 |
The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation |
Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
|
EP0710673A3
(de)
|
1990-05-21 |
1996-08-07 |
Toppan Printing Co Ltd |
Derivate von Cyclodextrinen
|
JP2556236B2
(ja)
*
|
1991-08-29 |
1996-11-20 |
田辺製薬株式会社 |
β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
|
ATE156019T1
(de)
*
|
1991-10-16 |
1997-08-15 |
Schering Corp |
Lipophile zusammensetzungen von oligosaccharid- antibiotikasalzen
|
DE4204315A1
(de)
*
|
1992-02-13 |
1993-08-19 |
Consortium Elektrochem Ind |
Cyclodextringlycoside und verfahren zu ihrer herstellung
|
US5403828A
(en)
*
|
1992-08-13 |
1995-04-04 |
American Maize-Products Company |
Purification of cyclodextrin complexes
|
US5629327A
(en)
*
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6114355A
(en)
*
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
US8143283B1
(en)
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
DE4309579C3
(de)
*
|
1993-03-24 |
2000-01-27 |
Sanol Arznei Schwarz Gmbh |
Pharmazeutische Zusammensetzung in Form einer Packung
|
DE4313408A1
(de)
*
|
1993-04-23 |
1994-10-27 |
Boehringer Mannheim Gmbh |
Cyclodextrin-Biocid-Komplex
|
HU213200B
(en)
*
|
1993-05-12 |
1997-03-28 |
Chinoin Gyogyszer Es Vegyeszet |
The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
|
RU2135176C1
(ru)
*
|
1993-12-14 |
1999-08-27 |
Эли Лилли Энд Компани |
Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
|
US5443824A
(en)
*
|
1994-03-14 |
1995-08-22 |
Piacquadio; Daniel J. |
Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
|
DE4429229A1
(de)
*
|
1994-08-18 |
1996-02-22 |
Consortium Elektrochem Ind |
Cyclodextrinderivate mit mindestens einem stickstoffhaltigen Heterozyklus, ihre Herstellung und Verwendung
|
EP0709099A3
(de)
*
|
1994-09-28 |
1996-07-24 |
Senju Pharma Co |
Wässrige Suspension zur nasalen Verabreichung enthaltend Cyclodextrin
|
US5468502A
(en)
*
|
1994-12-20 |
1995-11-21 |
American Home Products Corporation |
Ibuprofen enhancing solvent system
|
BE1008978A5
(fr)
*
|
1994-12-27 |
1996-10-01 |
Solvay |
Adjuvants pour vaccins.
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
DE19505263A1
(de)
*
|
1995-02-16 |
1996-08-22 |
Consortium Elektrochem Ind |
Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
|
WO1996041646A2
(en)
*
|
1995-06-13 |
1996-12-27 |
Dyer, Alison, Margaret |
Pharmaceutical compositions containing lornoxicam and cyclodextrin
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
HUT75956A
(en)
*
|
1995-11-29 |
1997-05-28 |
Cyclolab |
Pharmaceutical composition containing thyroxine
|
GB9605705D0
(en)
|
1996-03-19 |
1996-05-22 |
Pfizer Ltd |
Therapeutic agents
|
JP2000509374A
(ja)
|
1996-04-19 |
2000-07-25 |
アルファ セラピュティック コーポレイション |
凍結乾燥した血液タンパク質のウイルス不活性化方法
|
UA57734C2
(uk)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Комплекси включення арилгетероциклічних солей
|
US5906981A
(en)
*
|
1996-06-04 |
1999-05-25 |
Troy Corporation |
Halopropargyl inclusion complexes
|
DK1586322T3
(da)
*
|
1996-11-05 |
2008-12-01 |
Childrens Medical Center |
Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer
|
KR100435426B1
(ko)
*
|
1996-11-29 |
2004-08-16 |
주식회사 포스코 |
구조 이성질체의 분리에 유용한 6-디메틸옥틸실릴-2,3-디에틸-베타-시클로덱스트린 및 그 제조방법
|
KR100411289B1
(ko)
*
|
1996-11-29 |
2004-02-14 |
주식회사 포스코 |
회전장애 이성질체의 분리에 유용한 6-알릴디메틸실릴-2,3-디에 틸-베타-시클로덱스트린 및 그 제조방법
|
DE19713092A1
(de)
*
|
1997-03-27 |
1998-10-01 |
Wacker Chemie Gmbh |
Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
US5874418A
(en)
*
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
EP0986403B1
(de)
*
|
1997-06-13 |
2003-11-12 |
Cydex Inc. |
Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
|
GB9713149D0
(en)
*
|
1997-06-21 |
1997-08-27 |
Pfizer Ltd |
Pharmaceutical formulations
|
EP0889056B1
(de)
*
|
1997-07-01 |
2006-04-12 |
Pfizer Products Inc. |
Verfahren zur Herstellung von einem Cyclodextrin
|
US6391862B1
(en)
*
|
1997-10-14 |
2002-05-21 |
The Texas A&M University System |
Chiral resolving agents for enantioseparations
|
NZ505951A
(en)
*
|
1998-02-23 |
2003-02-28 |
Cyclops Ehf |
A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening
|
US6699849B1
(en)
|
1998-02-23 |
2004-03-02 |
Cyclops, Ehf. |
Cyclodextrin complexes of benzodiazepines
|
US6048736A
(en)
*
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
US6673828B1
(en)
*
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
DE19825486C2
(de)
*
|
1998-06-08 |
2000-07-06 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit supramolekularen Hohlraummolekülen, Verfahren zu deren Herstellung und deren Verwendung
|
NZ330726A
(en)
*
|
1998-06-18 |
2000-10-27 |
Dec Res |
Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
|
US20040152664A1
(en)
*
|
1998-09-02 |
2004-08-05 |
Allergan, Inc. |
Prednisolone compositions
|
EP1109581A1
(de)
|
1998-09-02 |
2001-06-27 |
Allergan Sales, Inc. |
Geschützte cyclodextrin-enthaltende zusammensetzungen
|
US20020198174A1
(en)
*
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
PL195280B1
(pl)
|
1999-01-21 |
2007-08-31 |
Bristol Myers Squibb Co |
Kompleks inhibitora RAS-farnezylotransferazy o ulepszonej rozpuszczalności w wodzie i trwałości oraz kompozycja inhibitora RAS-farnezylotransferazy
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
GB9915231D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Pfizer Ltd |
Pharmaceutical complex
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
DE19939662A1
(de)
|
1999-08-20 |
2001-02-22 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit Hohlraumverbindungen, Verfahren zur deren Herstellung und deren Verwendung
|
GB9921958D0
(en)
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
|
GB9921954D0
(en)
*
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
US6689378B1
(en)
|
1999-12-28 |
2004-02-10 |
Kimberly-Clark Worldwide, Inc. |
Cyclodextrins covalently bound to polysaccharides
|
US6677256B1
(en)
|
1999-12-28 |
2004-01-13 |
Kimberly-Clark Worldwide, Inc. |
Fibrous materials containing activating agents for making superabsorbent polymers
|
CN1450918A
(zh)
*
|
1999-12-28 |
2003-10-22 |
金伯利-克拉克环球有限公司 |
超吸收性聚合物
|
SK282717B6
(sk)
*
|
2000-03-10 |
2002-11-06 |
�Stav Experiment�Lnej Farmakol�Gie Sav |
Spôsob prípravy ultravysokomolekulových hyalurónanov
|
MXPA02009665A
(es)
*
|
2000-03-31 |
2005-09-08 |
Celgene Corp |
Inhibicion de actividad de ciclooxigenasa-2.
|
EP1287039A1
(de)
*
|
2000-04-28 |
2003-03-05 |
University College Dublin |
Ampiphile makrozyklische derivate und ihre analoge
|
EP1278549B1
(de)
*
|
2000-05-02 |
2008-12-10 |
Theravance, Inc. |
Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
ATE407134T1
(de)
|
2000-05-26 |
2008-09-15 |
Pfizer |
Triazolyltropanderivate als ccr5-modulatoren
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6468989B1
(en)
|
2000-07-13 |
2002-10-22 |
Dow Pharmaceutical Sciences |
Gel compositions containing metronidazole
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
US20070225379A1
(en)
*
|
2001-08-03 |
2007-09-27 |
Carrara Dario Norberto R |
Transdermal delivery of systemically active central nervous system drugs
|
ATE356636T1
(de)
*
|
2000-08-03 |
2007-04-15 |
Antares Pharma Ipl Ag |
Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
|
US20040198706A1
(en)
*
|
2003-03-11 |
2004-10-07 |
Carrara Dario Norberto R. |
Methods and formulations for transdermal or transmucosal application of active agents
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
US7198801B2
(en)
*
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
PE20020300A1
(es)
*
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
WO2002064083A2
(en)
*
|
2000-11-30 |
2002-08-22 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
US6566556B2
(en)
*
|
2000-12-19 |
2003-05-20 |
Nippon Shokubai Co., Ltd. |
Method for production of alkanolamine and apparatus therefor
|
JP2005503446A
(ja)
*
|
2001-01-11 |
2005-02-03 |
イーストマン ケミカル カンパニー |
シクロデキストリンスルホネート、ゲスト包接錯体、その製造方法及び関連物質
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
US7034013B2
(en)
*
|
2001-03-20 |
2006-04-25 |
Cydex, Inc. |
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
|
WO2002085860A1
(en)
|
2001-04-10 |
2002-10-31 |
Pfizer Limited |
Pyrazole derivatives for treating hiv
|
BR0102252B1
(pt)
*
|
2001-04-10 |
2013-10-22 |
|
Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
|
YU81503A
(sh)
*
|
2001-05-01 |
2006-08-17 |
Pfizer Products Inc. |
Postupak za proizvodnju farmaceutskog preparata sa niskom dozom, koji ima uniformnu raspodelu i snagu leka
|
MY140679A
(en)
|
2001-05-24 |
2010-01-15 |
Avanir Pharmaceuticals |
Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
EP1269994A3
(de)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
US7141540B2
(en)
*
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
EP1461044A4
(de)
*
|
2001-12-03 |
2007-06-13 |
Novacea Inc |
Pharmazeutische zusammensetzungen mit aktiven vitamin-d-verbindungen
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
US6881726B2
(en)
|
2001-12-24 |
2005-04-19 |
Dow Pharmaceutical Sciences |
Aqueous compositions containing metronidazole
|
KR20040083493A
(ko)
|
2002-02-01 |
2004-10-02 |
화이자 프로덕츠 인크. |
콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출형제약상 제형
|
MXPA04007737A
(es)
|
2002-02-11 |
2004-10-15 |
Pfizer |
Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4.
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
US20030164219A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Joerg Brahm |
Headliner/duct assembly and welding process therefor
|
MXPA04008173A
(es)
*
|
2002-02-22 |
2004-11-26 |
Pharmacia Corp |
Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
|
JP2005521690A
(ja)
*
|
2002-02-22 |
2005-07-21 |
ファルマシア・コーポレーション |
ゴム系を含む眼科用製剤
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
KR100451485B1
(ko)
*
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
DE10215942A1
(de)
*
|
2002-04-11 |
2003-10-23 |
Bayer Ag |
Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
US6869939B2
(en)
*
|
2002-05-04 |
2005-03-22 |
Cydex, Inc. |
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
NZ536908A
(en)
*
|
2002-05-17 |
2008-09-26 |
Celgene Corp |
Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
EP2272512A1
(de)
|
2002-05-17 |
2011-01-12 |
Celgene Corporation |
Pharmazeutische Zusammensetzungen zur Behandlung von Krebs
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US6818662B2
(en)
*
|
2002-05-28 |
2004-11-16 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
DE60327225D1
(de)
*
|
2002-08-20 |
2009-05-28 |
Bristol Myers Squibb Co |
Aripiprazol-komplex-formulierung und verfahren
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
AU2003272260A1
(en)
*
|
2002-09-09 |
2004-03-29 |
Josef Pitha |
Verifiable absorption drug delivery form based on cyclodextrins
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
WO2004024126A1
(en)
*
|
2002-09-13 |
2004-03-25 |
Cydex, Inc. |
Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
|
US20040053895A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US20040058895A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
EP1900369A1
(de)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
WO2004034962A2
(en)
*
|
2002-10-15 |
2004-04-29 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US7001893B2
(en)
*
|
2002-10-28 |
2006-02-21 |
Council Of Scientific And Industrial Research |
Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
|
CA2505131A1
(en)
|
2002-11-06 |
2004-05-27 |
Celgene Corporation |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US20050026877A1
(en)
*
|
2002-12-03 |
2005-02-03 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
KR20090118994A
(ko)
|
2002-12-13 |
2009-11-18 |
워너-램버트 캄파니 엘엘씨 |
하부요로증상을 치료하기 위한 알파-2-델타 리간드
|
US7186692B2
(en)
*
|
2002-12-17 |
2007-03-06 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
US7166575B2
(en)
*
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
WO2004056314A2
(en)
*
|
2002-12-17 |
2004-07-08 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
|
US7229966B2
(en)
*
|
2002-12-17 |
2007-06-12 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
JP4817068B2
(ja)
*
|
2003-01-14 |
2011-11-16 |
イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド |
全身性エリテマトーデスの治療のためのペプチドの非経口製剤
|
CA2513331A1
(en)
|
2003-01-14 |
2004-08-05 |
Teva Pharmaceutical Industries Ltd |
Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
|
EP1460064A1
(de)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide als beta-2 Agonisten
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
US20050020546A1
(en)
*
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
EP1633770B1
(de)
|
2003-06-13 |
2015-04-29 |
Alnylam Europe AG |
Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus
|
PT1664036E
(pt)
|
2003-09-03 |
2012-02-16 |
Pfizer |
Compostos de benzimidazolona que possuem actividade agonística do receptor 5-ht4
|
US7875630B2
(en)
|
2003-09-03 |
2011-01-25 |
Glaxo Group Limited |
Process salts compositions and use
|
WO2005023308A1
(en)
*
|
2003-09-05 |
2005-03-17 |
Maxygen Holdings Ltd. |
Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
KR100828218B1
(ko)
|
2003-09-12 |
2008-05-07 |
화이자 인코포레이티드 |
알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
|
ATE380813T1
(de)
|
2003-10-03 |
2007-12-15 |
Pfizer |
Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
|
PT1670433E
(pt)
*
|
2003-10-10 |
2012-02-08 |
Ferring Bv |
Fórmula farmacológica transdérmica para a minimização de resíduos na pele
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US7129042B2
(en)
*
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
AP2006003637A0
(en)
|
2003-11-06 |
2006-06-30 |
Celgene Corp |
Methods and compositions using thalidomide for thetreatment and management of cancers and other diseases
|
AU2004292445B2
(en)
|
2003-11-21 |
2010-02-04 |
Zalicus Inc. |
Methods and reagents for the treatment of inflammatory disorders
|
AU2004296863B2
(en)
*
|
2003-12-08 |
2008-12-11 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Synergistic anti-cancer compositions
|
DK1691811T3
(da)
|
2003-12-11 |
2014-10-20 |
Sunovion Pharmaceuticals Inc |
Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
US20070020298A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
US20070020196A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
BRPI0418276B8
(pt)
*
|
2003-12-31 |
2021-05-25 |
Cydex Pharmaceuticals Inc |
formulação líquida inalável compreeendendo budesonida
|
JP2007518788A
(ja)
|
2004-01-22 |
2007-07-12 |
ファイザー・インク |
バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
|
ATE375977T1
(de)
|
2004-01-22 |
2007-11-15 |
Pfizer |
Sulfonamidderivate zur behandlung von krankheiten
|
ME00557A
(en)
|
2004-01-22 |
2011-12-20 |
|
Sulfonamide derivatives for the treatment of diseases
|
US7632485B2
(en)
|
2004-02-24 |
2009-12-15 |
Massachusetts General Hospital |
Catalytic radiofluorination
|
EP1730751B1
(de)
*
|
2004-03-12 |
2009-10-21 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Magnetoresistives medium
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
EP1735284A1
(de)
|
2004-03-18 |
2006-12-27 |
Pfizer Limited |
N-(1-arylpyrazol-4l)sulfonamide und deren verwendung als parasitizide
|
KR101224262B1
(ko)
*
|
2004-03-22 |
2013-01-21 |
셀진 코포레이션 |
면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
EP1730103B1
(de)
|
2004-03-23 |
2010-05-26 |
Pfizer Limited |
Als adrenozeptor geeignete formamidderivate
|
BRPI0418743A
(pt)
*
|
2004-04-14 |
2007-09-18 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
BRPI0418742A
(pt)
*
|
2004-04-14 |
2007-09-11 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
WO2005105827A2
(en)
|
2004-04-15 |
2005-11-10 |
Proteolix, Inc. |
Compounds for proteasome enzyme inhibition
|
DK3520779T3
(da)
|
2004-04-23 |
2022-03-21 |
Cydex Pharmaceuticals Inc |
DPI formulering indeholdende sulfoalkylethercyclodextrin
|
AU2005323437B2
(en)
|
2004-04-30 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a C5-modified pyrimidine
|
WO2005105763A1
(en)
|
2004-04-30 |
2005-11-10 |
Warner-Lambert Company Llc |
Substituted morpholine compounds for the treatment of central nervous system disorders
|
US20050250738A1
(en)
*
|
2004-05-06 |
2005-11-10 |
Mosher Gerold L |
Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
BRPI0510802A
(pt)
*
|
2004-05-10 |
2007-11-06 |
Proteolix Inc |
compostos para inibição de enzima
|
EP1595881A1
(de)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
EP1758891A2
(de)
|
2004-06-15 |
2007-03-07 |
Pfizer Japan Inc. |
Benzimidazoloncarbonsäurederivate
|
WO2006007412A2
(en)
*
|
2004-06-16 |
2006-01-19 |
Nastech Pharmaceutical Company Inc. |
Peptide yy formulations having increased stability and resistance to microbial agents
|
ES2382383T3
(es)
|
2004-06-17 |
2012-06-07 |
Infinity Discovery, Inc. |
Compuestos y procedimientos para inhibir la interacción de proteínas Bcl con componentes de unión
|
JP4084836B2
(ja)
|
2004-08-12 |
2008-04-30 |
ファイザー・インク |
p38MAPキナーゼインヒビターとしてのトリアゾロピリジニルスルファニル誘導体
|
BRPI0513915A
(pt)
|
2004-08-26 |
2008-05-20 |
Pfizer |
compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
|
EP2479172B1
(de)
*
|
2004-09-03 |
2013-10-09 |
Celgene Corporation |
Verfahren zur Herstellung von substituierten 2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolinen
|
US20070190070A1
(en)
*
|
2004-09-03 |
2007-08-16 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
EP2407462B1
(de)
|
2004-09-21 |
2014-07-30 |
Marshall Edwards, Inc. |
Substituierte Chromanderivate, Medikamente und therapeutische Verwendung
|
US8080675B2
(en)
|
2004-09-21 |
2011-12-20 |
Marshall Edwards, Inc. |
Chroman derivatives, medicaments and use in therapy
|
EP1809618B1
(de)
|
2004-09-21 |
2013-07-17 |
Marshall Edwards, Inc. |
Chromanderivate, medikamente und anwendung in der therapie
|
US20060078955A1
(en)
*
|
2004-10-13 |
2006-04-13 |
Lin-Zhi International |
Method for retrieving delta9-THC from oral fluid
|
GEP20084424B
(en)
*
|
2004-10-26 |
2008-07-10 |
Viktor Rybchuk |
Sedative and spasmolytic medicinal agent and method for the production thereof (variants)
|
JP2008518924A
(ja)
*
|
2004-10-28 |
2008-06-05 |
セルジーン・コーポレーション |
中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物
|
EP1809607B1
(de)
|
2004-11-02 |
2008-12-17 |
Pfizer, Inc. |
Sulfonylbenzimidazolderivate
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
GT200500317A
(es)
*
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
US20060105045A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Cyclodextrin solubilizers for liquid and semi-solid formulations
|
US20060105992A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
|
PL2260835T3
(pl)
*
|
2004-12-07 |
2013-08-30 |
Onyx Therapeutics Inc |
Kompozycja do hamowania proteasomu
|
US20060128653A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
US20060128654A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
DE102004060927B3
(de)
*
|
2004-12-17 |
2006-02-16 |
Schwan-Stabilo Schwanhäusser Gmbh & Co. Kg |
Behälter für mindestens einen länglichen Gegenstand
|
EP1674098A1
(de)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
|
CN101160117A
(zh)
*
|
2005-02-16 |
2008-04-09 |
阿尔扎公司 |
依泊汀-基药物的透皮释放装置和方法
|
SG174829A1
(en)
*
|
2005-02-18 |
2011-10-28 |
Surface Logix Inc |
Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
|
WO2006089276A2
(en)
*
|
2005-02-18 |
2006-08-24 |
Surface Logix, Inc. |
Pharmacokinetically improved compounds
|
CA2614223A1
(en)
|
2005-02-24 |
2006-08-31 |
Dr Pharma Nova, Llc |
A registry method and control system for dea schedule ii-v medicines
|
WO2006097817A1
(en)
|
2005-03-17 |
2006-09-21 |
Pfizer Japan Inc. |
N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
|
DE602006003416D1
(de)
|
2005-03-21 |
2008-12-11 |
Pfizer Ltd |
Substituierte triazolderivate als oxytocinantagonisten
|
JP2008534611A
(ja)
|
2005-03-30 |
2008-08-28 |
シェーリング コーポレイション |
抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
|
DK1871353T3
(da)
*
|
2005-04-15 |
2011-04-04 |
Einstein Coll Med |
Vitamin k til forebyggelse eller behandling af hududslæt sekundært til anti-EGFR-terapi
|
US8076293B2
(en)
|
2005-04-19 |
2011-12-13 |
Gabriel Stavros Panayi |
Use of BiP or a variant, homologue, derivative or fragment thereof in the manufacture of a medicament for the prevention or treatment of bone loss or bone resorption
|
WO2007124250A2
(en)
|
2006-04-21 |
2007-11-01 |
Antares Pharma Ipl Ag |
Methods of treating hot flashes with formulations for transdermal or transmucosal application
|
GT200600162A
(es)
*
|
2005-04-24 |
2007-03-14 |
|
Metodos para modular la funcion de la vejiga
|
BRPI0611435A2
(pt)
|
2005-05-04 |
2010-09-08 |
Pfizer Ltd |
derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
|
WO2006124726A2
(en)
*
|
2005-05-12 |
2006-11-23 |
The General Hospital Corporation |
Novel biotinylated compositions
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
WO2006125642A1
(en)
|
2005-05-27 |
2006-11-30 |
Antares Pharma Ipl Ag |
Methods and apparatus for transdermal or transmucosal application of testosterone
|
WO2006137958A1
(en)
*
|
2005-06-13 |
2006-12-28 |
Cargill Incorporated |
Cyclodextrin inclusion complexes and methods of preparing same
|
CN101223183A
(zh)
*
|
2005-06-13 |
2008-07-16 |
嘉吉公司 |
环糊精包合复合物及其制备方法
|
CA2611917A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Takeda Pharmaceutical Company Limited |
Injection
|
ATE456557T1
(de)
|
2005-06-15 |
2010-02-15 |
Pfizer Ltd |
Substituierte arylpyrazole zur verwendung gegen parasiten
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US20060287301A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mcnair Douglas |
Novel formulations for phenothiazines, including fluphenazine and its derivatives
|
SI2380887T1
(sl)
|
2005-06-30 |
2013-12-31 |
Celgene Corporation |
Postopki priprave spojin 4-amino-2-/2,6-dioksopiperidin-3-il)izoindolin -1,3-diona
|
US20070009531A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
|
US20070010487A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
US20070010465A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
|
US20070010486A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
CA2630087A1
(en)
*
|
2005-07-06 |
2007-01-18 |
Kanisa Pharmaceuticals, Inc. |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
US20070010485A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
AR054849A1
(es)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
US20070191306A1
(en)
*
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
MX2008002765A
(es)
|
2005-08-31 |
2008-04-07 |
Celgene Corp |
Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
US7744904B1
(en)
|
2005-09-26 |
2010-06-29 |
B.B. Scientific L.L.C. |
Stabilization of Clostridium botulinum neurotoxin complex
|
AU2013200204B9
(en)
*
|
2005-09-30 |
2015-03-05 |
Lundbeck Llc |
Novel parenteral carbamazepine formulation
|
US20100204178A1
(en)
*
|
2006-10-02 |
2010-08-12 |
James Cloyd |
Novel parenteral carbamazepine formulation
|
ES2708375T3
(es)
*
|
2005-09-30 |
2019-04-09 |
Lundbeck Pharmaceuticals Llc |
Nueva formulación parenteral de carbamazepina
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
BRPI0520654B8
(pt)
|
2005-10-26 |
2021-05-25 |
Cydex Pharmaceuticals Inc |
composições de sulfoalquil éter ciclodextrina e processo para preparação das mesmas
|
AU2011204957B2
(en)
*
|
2005-10-26 |
2013-12-05 |
Cydex Pharmaceuticals, Inc |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
CN100503647C
(zh)
|
2005-11-02 |
2009-06-24 |
南京师范大学 |
羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
|
JP5436860B2
(ja)
|
2005-11-09 |
2014-03-05 |
オニキス セラピューティクス, インク. |
酵素阻害のための化合物
|
EP1954320A2
(de)
*
|
2005-11-15 |
2008-08-13 |
Baxter International Inc. |
Zusammensetzungen mit lipoxygenase-hemmern und zyklodextrin
|
US8022054B2
(en)
|
2005-11-28 |
2011-09-20 |
Marinus Pharmaceuticals |
Liquid ganaxolone formulations and methods for the making and use thereof
|
PT1954292E
(pt)
*
|
2005-11-28 |
2014-08-04 |
Verrow Pharmaceuticals Inc |
Composições úteis para reduzir a nefrotoxicidade e métodos para a sua utilização
|
US7658913B2
(en)
|
2005-11-28 |
2010-02-09 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
US20070135586A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Shreyas Chakravarti |
Polyamide blend compositions formed article and process thereof
|
US20070232537A1
(en)
*
|
2005-12-19 |
2007-10-04 |
Nastech Pharmaceutical Company Inc. |
Intranasal pyy formulations with improved transmucosal pharmacokinetics
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
US20070191323A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Verus Pharmaceuticals, Inc. |
Stable corticosteroid mixtures
|
CL2007000775A1
(es)
*
|
2006-03-24 |
2008-01-25 |
Wyeth Corp |
Uso de compuestos derivados de benzofurano para el tratamiento de un desorden cognitivo.
|
CN101410112A
(zh)
*
|
2006-03-24 |
2009-04-15 |
惠氏公司 |
治疗抑郁症的新治疗组合
|
KR20080105105A
(ko)
*
|
2006-03-24 |
2008-12-03 |
와이어쓰 |
인지 장애 및 기타 장애의 치료방법
|
CL2007000774A1
(es)
*
|
2006-03-24 |
2008-03-07 |
Wyeth Corp |
Uso de compuestos derivados de diazepina condensada para tratar la incontinencia urinaria.
|
MX2008012092A
(es)
*
|
2006-03-24 |
2008-10-03 |
Wyeth Corp |
Tratamiento del dolor.
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
JP2009534388A
(ja)
|
2006-04-18 |
2009-09-24 |
イーケーアール セラピューティクス, インク. |
予備混合即時使用製薬製剤
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
CN100374468C
(zh)
*
|
2006-05-25 |
2008-03-12 |
重庆通量精细化工有限公司 |
水溶性磺烷基醚-β-环糊精的合成工艺
|
CA2654876A1
(en)
|
2006-06-12 |
2007-12-21 |
Sunesis Pharmaceuticals, Inc. |
1-8-naphthyridine compounds for the treatment of cancer
|
EP2027136A4
(de)
*
|
2006-06-13 |
2011-08-03 |
Cargill Inc |
Grossteilige cyclodextrin-einschlusskomplexe und verfahren zu deren herstellung
|
US7691852B2
(en)
|
2006-06-19 |
2010-04-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
WO2008003317A1
(en)
*
|
2006-07-03 |
2008-01-10 |
Genmab A/S |
Prevention of rash in patients undergoing anti-egfr therapy
|
AR061889A1
(es)
|
2006-07-13 |
2008-10-01 |
Medichem Sa |
Proceso mejorado para la preparacion de voriconazol
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
MX344865B
(es)
|
2006-08-02 |
2016-12-19 |
Sunesis Pharmaceuticals Inc |
Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
|
EP2054386B1
(de)
|
2006-08-03 |
2014-10-08 |
Trustees Of Tufts College |
Non-flushing-niacinanaloga und verfahren zu deren anwendung
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
US20080207731A1
(en)
|
2006-08-23 |
2008-08-28 |
Intellect Neurosciences, Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
CN100486645C
(zh)
*
|
2006-09-12 |
2009-05-13 |
南京师范大学 |
含有环糊精紫杉醇包合物的药物组合物及其制备方法
|
CN100411688C
(zh)
*
|
2006-09-12 |
2008-08-20 |
南京师范大学 |
含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
|
US8278355B2
(en)
|
2006-09-12 |
2012-10-02 |
Therexcell Pharma Inc. |
Isovaline for treatment of pain
|
EP2068853A2
(de)
|
2006-09-15 |
2009-06-17 |
Stevia APS |
Behandlung von insulinresistenz oder erkrankungen im zusammenhang mit insulinresistenz mit bicyclo[3.2.1]octanen wie steviol und isosteviol
|
US20080194519A1
(en)
*
|
2006-09-15 |
2008-08-14 |
Regents Of The University Of Minnesota |
Topiramate compositions and methods for their use
|
US20090239942A1
(en)
*
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
WO2008035195A1
(en)
|
2006-09-21 |
2008-03-27 |
Raqualia Pharma Inc. |
Benzimidazole derivatives as selective acid pump inhibitors
|
RS56279B1
(sr)
|
2006-09-26 |
2017-12-29 |
Celgene Corp |
5-supstituisani derivati hinazolinona kao antitumorski agensi
|
JP2010506839A
(ja)
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
乳光の低減を伴う方法および組成物
|
NZ575624A
(en)
|
2006-10-18 |
2012-02-24 |
Pfizer Prod Inc |
Biaryl ether urea compounds
|
CA2666539A1
(en)
|
2006-10-23 |
2008-05-02 |
Pfizer Inc. |
Substituted phenylmethyl bicyclocarboxyamide compounds
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
BRPI0719096A2
(pt)
*
|
2006-11-21 |
2013-12-03 |
Novartis Ag |
Formulação parenteral estavel contendo uminibidor de rsv de uma estrutura de benzodiazepina
|
WO2008065142A1
(en)
*
|
2006-11-29 |
2008-06-05 |
N.V. Organon |
Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
|
WO2008067991A2
(en)
*
|
2006-12-08 |
2008-06-12 |
Antares Pharma Ipl Ag |
Skin-friendly drug complexes for transdermal administration
|
JP2010514794A
(ja)
*
|
2006-12-27 |
2010-05-06 |
カーギル インコーポレイテッド |
シクロデキストリン封入複合体および該複合体を調製する方法
|
EP2131849B1
(de)
*
|
2007-03-02 |
2011-10-26 |
The University Of Wollongong |
Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
|
ES2541454T3
(es)
|
2007-03-02 |
2015-07-20 |
Wyeth Llc |
Uso de cobre y glutamato en cultivos celulares para producción de polipéptidos
|
ES2855700T3
(es)
*
|
2007-04-27 |
2021-09-24 |
Cydex Pharmaceuticals Inc |
Formulaciones que contienen clopidogrel y sulfoalquil éter-ciclodextrina y métodos de uso
|
US7960353B2
(en)
*
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
US20080283693A1
(en)
*
|
2007-05-15 |
2008-11-20 |
Evans Michael J F |
Propulsion apparatus and system
|
EP2148692B1
(de)
|
2007-05-25 |
2017-01-25 |
Ipsen Pharma S.A.S. |
Mit hydantoin modifizierte melanocortin-rezeptorliganden
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
TWI428132B
(zh)
*
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
癌症化療效果之強化
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
WO2009018326A2
(en)
*
|
2007-07-31 |
2009-02-05 |
Limerick Biopharma, Inc. |
Soluble pyrone analogs methods and compositions
|
WO2009020590A1
(en)
*
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
EP2215087B1
(de)
|
2007-09-05 |
2013-12-18 |
Rigel Pharmaceuticals, Inc. |
Xinafoatsalz von n4-(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-yl]-5-fluor-n2-[3-(methylaminocarbonylmethylenoxy)phenyl]-2,4-pyrimidindiamin
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
SG10201503486XA
(en)
|
2007-09-26 |
2015-06-29 |
Celgene Corp |
6-, 7-, Or 8-Substituted Quinazolinone Derivatives And Compositions Comprising And Methods Of Using The Same
|
MY173938A
(en)
|
2007-10-04 |
2020-02-27 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
MX2010004350A
(es)
*
|
2007-10-22 |
2010-05-19 |
Sunesis Pharmaceuticals Inc |
Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
|
US8192721B2
(en)
*
|
2007-12-13 |
2012-06-05 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
|
US20090232796A1
(en)
*
|
2008-02-20 |
2009-09-17 |
Corral Laura G |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
KR20100129308A
(ko)
*
|
2008-02-28 |
2010-12-08 |
다케다 야쿠힌 고교 가부시키가이샤 |
약학 조성물
|
US8815953B2
(en)
*
|
2008-03-13 |
2014-08-26 |
Spectrum Pharmaceuticals, Inc. |
Formulations of vitamin K analogs for topical use
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
US7635773B2
(en)
*
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
MX2010011882A
(es)
*
|
2008-04-30 |
2011-02-25 |
Neutron Row |
Metodos para utilizar un factor de liberacion de corticotropina para el tratamiento de cancer.
|
WO2009137611A2
(en)
*
|
2008-05-06 |
2009-11-12 |
Board Of Regents, The University Of Texas System |
Treatment of pulmonary fungal infection with voriconazole via inhalation
|
US20110144202A1
(en)
*
|
2008-06-16 |
2011-06-16 |
Uwe Marx |
Concentrated oxaliplatin solution and its method of preparation
|
US20100022635A1
(en)
*
|
2008-07-28 |
2010-01-28 |
University Of Kansas |
Heat shock protein 90 inhibitor dosing methods
|
EP2328890B1
(de)
|
2008-08-06 |
2012-01-25 |
Pfizer Inc. |
6-substituierte 2-heterocyclylaminopyrazinverbindungen als chk-1-inhibitoren
|
JP2012500809A
(ja)
|
2008-08-29 |
2012-01-12 |
ノボゲン リサーチ ピーティーワイ リミテッド |
免疫調節活性
|
EP2163253B1
(de)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
|
KR20110073584A
(ko)
|
2008-10-21 |
2011-06-29 |
오닉스 세라퓨틱스, 인크. |
펩티드 에폭시케톤과의 병용 요법
|
CN102596196A
(zh)
*
|
2008-10-22 |
2012-07-18 |
诺沃根研究控股有限公司 |
用于诱导程序性细胞死亡的方法
|
KR20190079702A
(ko)
|
2008-10-24 |
2019-07-05 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
Dmd를 위한 다중 엑손 스키핑 조성물
|
BRPI0919942B1
(pt)
|
2008-10-29 |
2019-02-19 |
Celgene Corporation |
Composto, composição farmacêutica que o compreende e uso do referido composto
|
WO2010053487A1
(en)
|
2008-11-07 |
2010-05-14 |
Cydex Pharmaceuticals, Inc. |
Composition containing sulfoalkyl ether cyclodextrin and latanoprost
|
CN104958296B
(zh)
*
|
2008-11-15 |
2017-12-01 |
麦林塔医疗有限公司 |
抗微生物组合物
|
CA2741511C
(en)
|
2008-11-21 |
2017-01-24 |
Raqualia Pharma Inc. |
Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
|
JP5749176B2
(ja)
|
2008-12-16 |
2015-07-15 |
スノビオン プハルマセウトイカルス インコーポレイテッド |
トリプル再取込み阻害剤及びそれらの使用方法
|
US20120027722A1
(en)
|
2008-12-17 |
2012-02-02 |
Medical Research Council |
Hepatitis c virus combination therapy
|
CA2748066C
(en)
|
2008-12-31 |
2017-06-27 |
Anantha Sudhakar |
Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
|
ES2536191T3
(es)
|
2009-01-12 |
2015-05-21 |
Pfizer Limited |
Derivados de sulfonamida
|
WO2010082813A1
(en)
|
2009-01-13 |
2010-07-22 |
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam |
Method of treating cancer
|
PT2387580E
(pt)
|
2009-01-14 |
2014-10-30 |
Novacta Biosystems Ltd |
Derivativos da desoxiactagardina
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
JP5731407B2
(ja)
|
2009-02-04 |
2015-06-10 |
ノヴァクタ バイオシステムズ リミティッド |
アクタガルジン誘導体
|
CN102387798A
(zh)
|
2009-02-10 |
2012-03-21 |
细胞基因公司 |
供治疗、预防和控制结核病的pde4调节剂的使用方法及包含其的组合物
|
SG173639A1
(en)
|
2009-02-11 |
2011-09-29 |
Sunovion Pharmaceuticals Inc |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
US20120053159A1
(en)
|
2009-02-11 |
2012-03-01 |
Muller George W |
Isotopologues of lenalidomide
|
SG173855A1
(en)
|
2009-02-27 |
2011-09-29 |
Sunesis Pharmaceuticals Inc |
Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
|
EP2406281B1
(de)
|
2009-03-12 |
2016-02-17 |
Haase Investments UG |
Varianten des knochenmorphogenetischen proteins 2 (bone morphogenetic protein 2, bmp2) mit reduzierter bmp-antagonistischer empfindlichkeit
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
EP2233502A1
(de)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
WO2010120614A1
(en)
|
2009-04-14 |
2010-10-21 |
Eli Lilly And Company |
Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
|
EP3100728B1
(de)
*
|
2009-05-13 |
2019-11-20 |
Cydex Pharmaceuticals, Inc. |
Pharmazeutische zusammensetzungen mit prasugrel- und cyclodextrinderivaten sowie verfahren zur herstellung und verwendung davon
|
US20120134969A1
(en)
|
2009-05-25 |
2012-05-31 |
Hiroshi Handa |
Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
|
AU2010252609A1
(en)
|
2009-05-29 |
2011-11-10 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
US20100311838A1
(en)
|
2009-05-29 |
2010-12-09 |
Pipkin James D |
Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
|
US8492538B1
(en)
|
2009-06-04 |
2013-07-23 |
Jose R. Matos |
Cyclodextrin derivative salts
|
BRPI1012097A2
(pt)
|
2009-06-10 |
2016-03-22 |
Sunovion Pharmaceuticals Inc |
antagonistas e antagonistas inversos de histamina h3 e métodos de uso dos mesmos.
|
EP2266563A1
(de)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
|
RU2012101214A
(ru)
|
2009-06-16 |
2013-07-27 |
Пфайзер Инк. |
Лекарственные формы апиксабана
|
EP2349323A2
(de)
|
2009-06-24 |
2011-08-03 |
Stephen Evans-Freke |
Verfahren zur verwendung eines corticotropin freisetzenden faktors zur krebsbehandlung
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
DE102009034368A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
ES2573982T3
(es)
|
2009-08-19 |
2016-06-13 |
Ratiopharm Gmbh |
Proceso para la producción de coevaporados y complejos que comprenden voriconazol y ciclodextrina
|
EP2475664A2
(de)
|
2009-09-11 |
2012-07-18 |
Sunovion Pharmaceuticals Inc. |
Inverse histamin-h3-agonisten und antagonisten sowie anwendungsverfahren dafür
|
WO2011041593A1
(en)
*
|
2009-09-30 |
2011-04-07 |
University Of Kansas |
Novobiocin analogues and treatment of polycystic kidney disease
|
CN102712928B
(zh)
|
2009-11-13 |
2017-08-04 |
萨雷普塔治疗公司 |
反义抗病毒化合物及治疗流感病毒感染的方法
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
CN102781443A
(zh)
|
2009-11-19 |
2012-11-14 |
细胞基因公司 |
用于治疗结节病的阿普斯特
|
WO2011064558A2
(en)
|
2009-11-30 |
2011-06-03 |
Cipla Limited |
Pharmaceutical composition
|
CN104193761B
(zh)
|
2009-12-04 |
2017-10-17 |
桑诺维恩药品公司 |
多环化合物及其使用方法
|
WO2011075699A2
(en)
|
2009-12-18 |
2011-06-23 |
Sunovion Pharmaceuticals Inc. |
Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
|
EP2516669B1
(de)
|
2009-12-21 |
2016-10-12 |
Advanced Liquid Logic, Inc. |
Enzymassays auf einem tropfenaktuator
|
SG181891A1
(en)
|
2009-12-22 |
2012-07-30 |
Celgene Corp |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
MX2012007402A
(es)
|
2009-12-23 |
2012-08-23 |
Takeda Pharmaceutical |
Pirrolidinonas heteroaromaticas fusionadas como inhibidores de tirosina cinasa esplenica (syk).
|
CA2786266A1
(en)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
US20120309676A1
(en)
|
2010-02-02 |
2012-12-06 |
Sjoerd Nicolaas Wadman |
Lantibiotic Salts
|
RS59275B1
(sr)
|
2010-02-11 |
2019-10-31 |
Celgene Corp |
Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
|
EP2539358A1
(de)
|
2010-02-25 |
2013-01-02 |
Pfizer Limited |
Peptidanaloga
|
EP2542238B1
(de)
|
2010-03-01 |
2015-08-12 |
Onyx Therapeutics, Inc. |
Verbindungen zur immunproteasomhemmung
|
KR20130038838A
(ko)
*
|
2010-03-12 |
2013-04-18 |
셀진 코포레이션 |
레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
|
EP2545173A2
(de)
|
2010-03-12 |
2013-01-16 |
Sarepta Therapeutics, Inc. |
Antisense-modulation von nukleären hormonrezeptoren
|
MX2012011604A
(es)
|
2010-04-07 |
2013-02-27 |
Onyx Therapeutics Inc |
Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
|
CA2796967C
(en)
|
2010-05-04 |
2015-12-01 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
EP2569431B1
(de)
|
2010-05-13 |
2015-09-23 |
Sarepta Therapeutics, Inc. |
Methoden zur identifizierung von verbindungen, die die signalaktivität von interleukin-17- und interleukin-23 modulieren
|
CN103037904B
(zh)
|
2010-05-26 |
2015-04-22 |
纽柔菲克西亚有限公司 |
2-亚氨基生物素制剂及其应用
|
EP3318561B1
(de)
|
2010-05-26 |
2021-12-22 |
Sunovion Pharmaceuticals Inc. |
Heteroarylverbindungen und verfahren zur verwendung davon
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
JP5925771B2
(ja)
|
2010-06-24 |
2016-05-25 |
トラスティーズ オブ タフツ カレッジ |
ナイアシン模倣体、およびその使用方法
|
US8937063B2
(en)
|
2010-06-24 |
2015-01-20 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
HRP20211686T1
(hr)
|
2010-06-29 |
2022-03-04 |
Merck Sharp & Dohme Corp. |
Formulacije intravenozne otopine sa posakonazolom, stabilizirane supstituiranim beta-ciklodekstrinom
|
NL2005052C2
(en)
|
2010-07-07 |
2012-01-10 |
Caroline Haaften |
Xanthanodien for the treatment of cancer.
|
EP2590951B1
(de)
|
2010-07-09 |
2015-01-07 |
Pfizer Limited |
Benzolsulfonamide als kaliumkanalhemmer
|
ES2526675T3
(es)
|
2010-07-09 |
2015-01-14 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
|
ES2532356T3
(es)
|
2010-07-09 |
2015-03-26 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
|
WO2012007861A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
JP2013531030A
(ja)
|
2010-07-12 |
2013-08-01 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネルの阻害剤としてのn−スルホニルベンズアミド
|
EP2593427B1
(de)
|
2010-07-12 |
2014-12-24 |
Pfizer Limited |
Sulfonamidderivate als nav1.7-inhibitoren zur schmerzbehandlung
|
WO2012007868A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
WO2012007877A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
EP2409699B1
(de)
|
2010-07-23 |
2014-04-30 |
Combino Pharm, S.L. |
Stabile Voriconazole-enthaltende Zusammensetzungen
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
WO2012025745A1
(en)
|
2010-08-24 |
2012-03-01 |
Imperial Innovations Limited |
Glycodendrimers of polypropyletherimine
|
DK2608782T3
(en)
|
2010-08-24 |
2016-09-05 |
Algiax Pharmaceuticals Gmbh |
New use of leflunomide malononitrilamider
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
PT2632451T
(pt)
|
2010-10-29 |
2017-12-14 |
Algiax Pharmaceuticals Gmbh |
Utilização de malononitrilamidas na dor neuropática
|
CA2816319C
(en)
|
2010-11-01 |
2020-06-30 |
Marshall Edwards, Inc. |
Isoflavonoid compounds and methods for the treatment of cancer
|
BR112013011991A2
(pt)
|
2010-11-15 |
2016-08-30 |
Viiv Healthcare Uk Ltd |
composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit.
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
CN103402980B
(zh)
|
2011-01-10 |
2016-06-29 |
细胞基因公司 |
作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
|
JP6106603B2
(ja)
|
2011-01-11 |
2017-04-05 |
スノビオン プハルマセウトイカルス インコーポレイテッド |
ヘテロアリール化合物及びその使用方法
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
WO2012100142A2
(en)
|
2011-01-20 |
2012-07-26 |
Cornell University |
Treatments for retinal disorders
|
ES2672238T3
(es)
|
2011-01-26 |
2018-06-13 |
Allergan, Inc. |
Composición androgénica para el tratamiento de una afección oftálmica
|
CN103338753A
(zh)
|
2011-01-31 |
2013-10-02 |
细胞基因公司 |
胞苷类似物的药物组合物及其使用方法
|
CN103384672B
(zh)
|
2011-02-25 |
2016-09-28 |
武田药品工业株式会社 |
N-取代的噁嗪并喋啶和噁嗪并喋啶酮
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
WO2012120365A1
(en)
|
2011-03-07 |
2012-09-13 |
Aurobindo Pharma Limited |
Stable pharmaceutical composition comprising ethinyl estradiol
|
TWI542349B
(zh)
|
2011-03-11 |
2016-07-21 |
西建公司 |
利用3-(5-胺基-2-甲基-4-氧基-4h-喹唑啉-3-基)-六氫吡啶-2,6-二酮治療癌症之方法
|
HUE037955T2
(hu)
|
2011-03-11 |
2018-09-28 |
Celgene Corp |
A 3-(5-amino-2-metil-4-oxo-4H-kinazolin-3-il)- piperidin-2,6-dion szilárd halmazállapotú formái, valamint gyógyászati készítményei és felhasználása
|
WO2012123353A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of benzofuranylsulfonates
|
WO2012123406A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of imidazotriazinones
|
US9090585B2
(en)
|
2011-03-28 |
2015-07-28 |
Deuterx, Llc |
2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
|
RU2464042C1
(ru)
*
|
2011-03-31 |
2012-10-20 |
Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" |
КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
|
MX2013011612A
(es)
|
2011-04-05 |
2013-10-17 |
Pfizer Ltd |
Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina.
|
WO2012138214A1
(en)
|
2011-04-08 |
2012-10-11 |
Brewster Lizzy Maritza |
Beta-guanidinopropionic acid for the treatment of hypertension
|
KR20140024914A
(ko)
|
2011-04-29 |
2014-03-03 |
셀진 코포레이션 |
예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
|
US9187463B2
(en)
|
2011-05-18 |
2015-11-17 |
Raqualia Pharma Inc. |
Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
WO2012163546A1
(en)
*
|
2011-06-03 |
2012-12-06 |
Ratiopharm Gmbh |
Pharmaceutical composition comprising dapagliflozin and cyclodextrin
|
KR101731155B1
(ko)
|
2011-06-15 |
2017-04-27 |
신톤 비.브이. |
안정화된 보리코나졸 조성물
|
WO2012177678A2
(en)
|
2011-06-22 |
2012-12-27 |
Celgene Corporation |
Isotopologues of pomalidomide
|
WO2012177714A1
(en)
|
2011-06-22 |
2012-12-27 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
WO2013009927A2
(en)
|
2011-07-11 |
2013-01-17 |
Advanced Liquid Logic, Inc. |
Droplet actuators and techniques for droplet-based assays
|
JP5898767B2
(ja)
|
2011-07-13 |
2016-04-06 |
ファイザー・リミテッドPfizer Limited |
エンケファリン類似体
|
WO2013012752A2
(en)
|
2011-07-15 |
2013-01-24 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
EP2739274A1
(de)
|
2011-08-02 |
2014-06-11 |
Pensieve Biosciences Cyprus Limited |
Behandlung von kognitiver störung
|
EP2739284A1
(de)
|
2011-08-02 |
2014-06-11 |
Pfizer Inc |
Crizotinib zur verwendung in der krebsbehandlung
|
EP2561863A1
(de)
|
2011-08-22 |
2013-02-27 |
Farmaprojects, S.A.U. |
Pharmazeutische Zusammensetzungen mit Voriconazol
|
KR20140078619A
(ko)
|
2011-09-18 |
2014-06-25 |
유로-셀띠끄 소시에떼 아노님 |
약학적 조성물
|
US10478505B2
(en)
|
2011-09-23 |
2019-11-19 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
MD20140037A2
(ro)
|
2011-10-26 |
2014-08-31 |
Pfizer Limited |
Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu
|
CA2853231C
(en)
|
2011-10-28 |
2020-08-04 |
Inhibitaxin Limited |
Pyridazine derivatives with autotaxin activity for use in therapy
|
EP2788487B1
(de)
|
2011-12-08 |
2018-04-04 |
Sarepta Therapeutics, Inc. |
Gegen humanes lmna gerichtete oligonucleotidanaloga
|
WO2013088315A1
(en)
|
2011-12-15 |
2013-06-20 |
Pfizer Limited |
Sulfonamide derivatives
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
WO2013096055A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CN104125953A
(zh)
|
2011-12-23 |
2014-10-29 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
EP2794591A1
(de)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
|
JP2015503515A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Bcl2と結合相手の相互作用を阻害するための化合物および組成物
|
CA2859873A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
TW201332572A
(zh)
|
2011-12-28 |
2013-08-16 |
Otsuka Pharma Co Ltd |
具有經取代的β-環糊精之藥物製劑
|
WO2013102826A1
(en)
|
2012-01-04 |
2013-07-11 |
Pfizer Limited |
N-aminosulfonyl benzamides
|
ES2758446T3
(es)
|
2012-01-23 |
2020-05-05 |
Sage Therapeutics Inc |
Formulaciones de esteroides neuroactivos que comprenden un complejo de alopregnanolona y sulfobutil éter beta-ciclodextrina
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
AR092790A1
(es)
|
2012-02-01 |
2015-05-06 |
Euro Celtique Sa |
Derivados bencimidazolicos del acido hidroxamico
|
EP2809655B1
(de)
|
2012-02-03 |
2015-08-12 |
Pfizer Inc |
Benziimidazol- und imidazopyridinderivate als natriumkanalmodulatoren
|
CA3132120C
(en)
|
2012-02-08 |
2023-10-24 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
TW201336527A
(zh)
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
DK3702374T3
(da)
|
2012-02-15 |
2022-06-27 |
Cydex Pharmaceuticals Inc |
Fremsgangsmåde til fremstilling for cyclodextrin-derivater
|
EP2817300B1
(de)
|
2012-02-21 |
2018-04-25 |
Celgene Corporation |
Feste formen von 3-(4-nitro-1-oxoisoindolin-2-yl)piperidin-2,6-dion
|
RU2615385C2
(ru)
|
2012-02-28 |
2017-04-04 |
Сидекс Фармасьютикалс, Инк. |
Композиции алкилированного циклодекстрина и способы их получения и применения
|
EP2819691A1
(de)
|
2012-03-02 |
2015-01-07 |
Erasmus University Medical Center Rotterdam |
Verfahren zur aktivierung von retroviren in latenten infizierten zellen und verbindungen zur verwendung darin
|
EP2822953B9
(de)
|
2012-03-06 |
2017-06-21 |
Pfizer Inc |
Makrocyclische derivate zur behandlung von proliferativen erkrankungen
|
WO2013148603A1
(en)
|
2012-03-27 |
2013-10-03 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives as as btk inhibitors
|
DK2831122T3
(da)
|
2012-03-30 |
2016-05-17 |
Sapiotec Gmbh |
Anthocyanidin-kompleks
|
KR101905239B1
(ko)
|
2012-03-30 |
2018-10-05 |
자피오텍 게엠베하 |
스타필로코쿠스 아우레우스에 대한 델피니딘의 용도
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
CN104519867A
(zh)
|
2012-05-11 |
2015-04-15 |
希普拉有限公司 |
药物组合物
|
PL2900637T3
(pl)
|
2012-05-15 |
2018-01-31 |
Novartis Ag |
Pirymidyna podstawiona tiazolem lub imidazolem, amidowe pochodne pirazyny i pirydyny i powiązane związki takie jak inhibitory abl1, abl2 i bcr-abl1 do leczenia nowotworu, specyficznych infekcji wirusowych i specyficznych zaburzeń cns
|
CU24265B1
(es)
|
2012-05-15 |
2017-07-04 |
Novartis Ag |
Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer
|
WO2013171640A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
WO2013171642A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
WO2013183985A1
(en)
|
2012-06-05 |
2013-12-12 |
Erasmus University Medical Center Rotterdam |
Method of treating cognitive impairment and compounds for use therein
|
CA2877736C
(en)
|
2012-06-29 |
2021-12-07 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
EP2869820A4
(de)
|
2012-07-09 |
2016-02-17 |
Onyx Therapeutics Inc |
Prodrugs von peptidepoxidketonproteaseinhibitoren
|
TW201414734A
(zh)
|
2012-07-10 |
2014-04-16 |
Takeda Pharmaceutical |
氮雜吲哚衍生物
|
CA2879139C
(en)
|
2012-07-18 |
2021-05-11 |
Onyx Therapeutics, Inc. |
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
AR094997A1
(es)
|
2012-08-09 |
2015-09-16 |
Celgene Corp |
Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos
|
HUE049569T2
(hu)
|
2012-08-09 |
2020-09-28 |
Celgene Corp |
Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése
|
CN104837491A
(zh)
|
2012-08-09 |
2015-08-12 |
细胞基因公司 |
利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6-二酮治疗癌症的方法
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
EP3441467A3
(de)
|
2012-08-31 |
2019-04-24 |
The General Hospital Corporation |
Biotinkomplexe zur behandlung und diagnose von morbus alzheimer
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
EA201590535A1
(ru)
|
2012-09-10 |
2015-07-30 |
Селджин Корпорейшн |
Способы лечения локально прогрессирующего запущенного рака молочной железы
|
US9533989B2
(en)
|
2012-09-18 |
2017-01-03 |
Ziarco Pharma Ltd. |
Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
|
CA2884848C
(en)
|
2012-09-28 |
2017-08-22 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
US20150250785A1
(en)
|
2012-10-04 |
2015-09-10 |
Pfizer Limited |
Tropomyosin-Related Kinase Inhibitors
|
CA2885259A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
WO2014053967A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
|
EP2909239A4
(de)
|
2012-10-22 |
2016-06-08 |
Cydex Pharmaceuticals Inc |
Alkylierte zusammensetzungen auf basis von cyclodextrin und verfahren zur herstellung und gebrauch derselben
|
JP5857168B2
(ja)
|
2012-11-08 |
2016-02-10 |
ファイザー・インク |
ドーパミンd1リガンドとしての複素芳香族化合物およびその使用
|
GEP201606598B
(en)
|
2012-11-08 |
2017-01-10 |
Pfizer |
Heteroaromatic compounds as dopamine d1 ligands
|
US20150290171A1
(en)
|
2012-11-09 |
2015-10-15 |
Celgene Corporation |
Methods for the treatment of bone loss
|
DK2919791T3
(da)
|
2012-11-15 |
2017-07-17 |
Sapiotec Gmbh |
Delphinidin-kompleks som antiflogistisk eller immunsuppressivt aktivt stof
|
BR112015011392A2
(pt)
|
2012-11-21 |
2017-07-11 |
Raqualia Pharma Inc |
formas polimórficas de ácidos, processo de preparação, composição farmacêutica e uso das mesmas
|
CA2889906A1
(en)
|
2012-11-29 |
2014-06-05 |
Sunovion Pharmaceuticals Inc. |
Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
|
DK2925327T3
(da)
|
2012-11-30 |
2024-03-25 |
Univ California |
Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
|
ES2609596T3
(es)
|
2012-12-03 |
2017-04-21 |
Pfizer Inc |
Moduladores selectivos de receptor de andrógenos novedosos
|
EP2931286B1
(de)
|
2012-12-11 |
2017-10-04 |
SapioTec GmbH |
Delphinidin zur bekämpfung von melanomzellen
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
EP3885439A1
(de)
|
2012-12-20 |
2021-09-29 |
Sarepta Therapeutics, Inc. |
Verbesserte exon-skipping-zusammensetzungen zur behandlung von muskeldystrophie
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
US9884844B2
(en)
|
2012-12-31 |
2018-02-06 |
Sunovion Pharmaceuticals, Inc. |
Heterocyclic compounds and methods of use thereof
|
WO2014110558A1
(en)
|
2013-01-14 |
2014-07-17 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
US9695145B2
(en)
|
2013-01-22 |
2017-07-04 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
MX359471B
(es)
|
2013-02-19 |
2018-09-28 |
Novartis Ag |
Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrogeno.
|
AU2014220354B2
(en)
|
2013-02-21 |
2018-02-01 |
Pfizer Inc. |
Solid forms of a selective CDK4/6 inhibitor
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
BR112015021000A2
(pt)
*
|
2013-03-14 |
2017-07-18 |
Allergan Inc |
composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação
|
HUE042218T2
(hu)
|
2013-03-14 |
2019-06-28 |
Sarepta Therapeutics Inc |
Exonátugrást elõsegítõ készítmények izomdisztrófia kezelésére
|
CN105378081B
(zh)
|
2013-03-14 |
2019-06-14 |
萨勒普塔医疗公司 |
用于治疗肌营养不良的外显子跳跃组合物
|
US20140329762A1
(en)
|
2013-03-15 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
EP2784083A1
(de)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
|
AU2014248263A1
(en)
|
2013-04-02 |
2015-10-15 |
Celgene Corporation |
Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
|
EP2792360A1
(de)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
EP2815749A1
(de)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
|
HUE062265T2
(hu)
|
2013-06-27 |
2023-10-28 |
Pfizer |
Heteroaromás vegyületek és azok alkalmazása dopamin D1 ligandumokként
|
EP3019158A1
(de)
|
2013-07-08 |
2016-05-18 |
AbbVie Inc. |
Stabilisierte pharmazeutische dosierungsformen mit atrasentan
|
GB201312737D0
(en)
*
|
2013-07-17 |
2013-08-28 |
Univ Greenwich |
Cyclodextrin
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
US20170305857A1
(en)
|
2013-12-20 |
2017-10-26 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
US9371321B2
(en)
|
2014-01-09 |
2016-06-21 |
Astrazeneca Ab |
Azaindole derivatives
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
CN103694376B
(zh)
|
2014-01-10 |
2016-04-13 |
凯莱英医药集团(天津)股份有限公司 |
一种制备磺丁基醚-β-环糊精的方法
|
EP3666273A3
(de)
|
2014-01-15 |
2020-10-28 |
Poxel SA |
Verfahren zur behandlung von neurologischen, stoffwechsel- und anderen erkrankungen unter verwendung enantiomerenreinen deuterium-angereicherten pioglitazons
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JP6523303B2
(ja)
|
2014-01-17 |
2019-05-29 |
ノバルティス アーゲー |
Shp2の活性を阻害するための1−ピリダジン/トリアジン−3−イル−ピペラジン/ピペリジン/ピロリジン誘導体およびその組成物
|
EP2913050A1
(de)
|
2014-02-28 |
2015-09-02 |
SapioTec GmbH |
Verfahren zur Herstellung eines Flurankomplexes
|
CA2941782C
(en)
|
2014-03-18 |
2022-08-23 |
Algiax Pharmaceuticals Gmbh |
2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
|
WO2015159175A1
(en)
|
2014-04-15 |
2015-10-22 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
|
US9868744B2
(en)
|
2014-04-25 |
2018-01-16 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
CR20160494A
(es)
|
2014-04-25 |
2016-12-20 |
Pfizer |
Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
|
AP2016009464A0
(en)
|
2014-04-25 |
2016-09-30 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
WO2015166370A1
(en)
|
2014-04-28 |
2015-11-05 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
JP6564394B2
(ja)
|
2014-04-28 |
2019-08-21 |
ファイザー・インク |
複素環式化合物およびそのドーパミンd1リガンドとしての使用
|
EP3140298A1
(de)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-assoziierte kinaseinhibitoren
|
PE20161475A1
(es)
|
2014-05-14 |
2017-01-08 |
Pfizer |
Pirazolopiridinas y pirazolopirimidinas
|
WO2015173684A1
(en)
|
2014-05-15 |
2015-11-19 |
Pfizer Inc. |
Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
|
ES2747989T3
(es)
|
2014-05-20 |
2020-03-12 |
Raqualia Pharma Inc |
Sal de derivado de benzisoxazol
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
CA2950390C
(en)
|
2014-05-30 |
2020-09-22 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
CA2950393A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
US9802945B2
(en)
|
2014-06-12 |
2017-10-31 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the GABAA receptor activity
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
JP6152495B1
(ja)
|
2014-06-17 |
2017-06-21 |
ファイザー・インク |
置換ジヒドロイソキノリノン化合物
|
EP3166642B1
(de)
|
2014-06-18 |
2020-06-03 |
Audevard |
Transdermale formulierungen von pergolid und verwendungen davon
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
TWI568365B
(zh)
*
|
2014-07-22 |
2017-02-01 |
蘇廷弘 |
抑菌複合物及其製造方法
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
PT3183295T
(pt)
|
2014-08-22 |
2023-11-03 |
Cydex Pharmaceuticals Inc |
Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
|
WO2016029004A1
(en)
|
2014-08-22 |
2016-02-25 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
US10017529B2
(en)
|
2014-09-16 |
2018-07-10 |
BioPharma Works LLC |
Metformin derivatives
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
EP3233829B1
(de)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidin und triazinderivate und deren verwendung als axl-inhibitoren
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
US9765000B2
(en)
|
2015-01-22 |
2017-09-19 |
Phytoplant Research S.L. |
Methods of purifying cannabinoids, compositions and kits thereof
|
EP3050574B1
(de)
|
2015-01-28 |
2019-10-09 |
Universite De Bordeaux |
Verwendung von Plerixafor zur Behandlung und/oder Vorbeugung von akuten Exazerbationen einer chronisch obstruktiver Lungenerkrankung
|
WO2016126618A1
(en)
|
2015-02-02 |
2016-08-11 |
Mei Pharma, Inc. |
Combination therapies
|
EP4059522A1
(de)
|
2015-02-06 |
2022-09-21 |
Marinus Pharmaceuticals, Inc. |
Intravenöse ganaxolonformulierungen und deren verwendung bei der behandlung von epileptischen zuständen und anderen anfallsstörungen
|
JP6584521B2
(ja)
|
2015-02-24 |
2019-10-02 |
ファイザー・インク |
抗がん剤として有用な置換ヌクレオシド誘導体
|
WO2016148674A1
(en)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugates for treating diseases
|
EP3939582A1
(de)
|
2015-03-19 |
2022-01-19 |
Cydex Pharmaceuticals, Inc. |
Zusammensetzungen mit silymarin und sulfoalkylethercyclodextrin und verfahren zur verwendung davon
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
NL2014614B1
(en)
|
2015-04-10 |
2017-01-25 |
Pld Biochemistry B V |
Method and means for increasing antibodies against Borrelia burgdorferi and increasing antigen of Borrelia burgdorferi.
|
WO2016195476A1
(en)
|
2015-05-29 |
2016-12-08 |
Erasmus University Medical Center Rotterdam |
Treatment of cardiac arrhythmias
|
JP6878316B2
(ja)
|
2015-06-19 |
2021-05-26 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物および組成物
|
CN112625028A
(zh)
|
2015-06-19 |
2021-04-09 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
US10975080B2
(en)
|
2015-06-19 |
2021-04-13 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
AU2016288246A1
(en)
|
2015-07-02 |
2018-02-01 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
WO2017007805A1
(en)
|
2015-07-09 |
2017-01-12 |
Gilead Sciences, Inc. |
Intravenous formulations of a late sodium current inhibitor
|
TN2017000544A1
(en)
|
2015-07-31 |
2019-04-12 |
Pfizer |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
|
WO2017059131A1
(en)
|
2015-09-30 |
2017-04-06 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
KR20180086423A
(ko)
|
2015-11-30 |
2018-07-31 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
다니릭신의 정맥내 투여를 위한 제제
|
EP3386983A1
(de)
|
2015-12-10 |
2018-10-17 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazin-derivate der formel (i) als gaba-rezeptormodulatoren zur verwendung bei der behandlung von epilepsie und schmerzen
|
DK3394045T3
(da)
|
2015-12-24 |
2021-08-16 |
Takeda Pharmaceuticals Co |
Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal.
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
WO2017120429A1
(en)
|
2016-01-07 |
2017-07-13 |
CS Pharmasciences, Inc. |
Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
AU2017208119B2
(en)
|
2016-01-15 |
2019-11-07 |
Pfizer Inc. |
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
|
BR112018016066A2
(pt)
*
|
2016-02-04 |
2019-01-02 |
Czap Res And Development Llc |
veículo de entrega, método para tratar um distúrbio gastrointestinal, uso do veículo de entrega, método para formular um veículo de entrega, formulação farmacêutica, método para formular acetaminofeno, substituição de refeição, complexo de inclusão, método para tratar um paciente, método para modular o microbioma
|
EP3426257A4
(de)
|
2016-03-08 |
2019-11-13 |
Sage Therapeutics, Inc. |
Neuroaktive steroide, zusammensetzungen und verwendungen davon
|
US11753626B2
(en)
|
2016-03-09 |
2023-09-12 |
Beijing Percans Oncology Co., Ltd. |
Tumor cell suspension cultures and related methods
|
WO2017173111A1
(en)
*
|
2016-03-31 |
2017-10-05 |
Takeda Pharmaceutical Company Limited |
Isoquinolinyl triazolone complexes
|
AU2017258642B2
(en)
|
2016-04-29 |
2023-08-31 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues targeting human LMNA
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
BR112018075663A2
(pt)
|
2016-06-14 |
2019-04-09 |
Novartis Ag |
compostos e composições para a inibição da atividade de shp2
|
EP3478697A1
(de)
|
2016-06-30 |
2019-05-08 |
Sarepta Therapeutics, Inc. |
Exon-skipping-oligomere für muskeldystrophie
|
KR102500936B1
(ko)
*
|
2016-07-22 |
2023-02-16 |
에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) |
살바이러스 화합물 및 이의 용도
|
AU2017304103A1
(en)
|
2016-07-29 |
2019-01-17 |
Pfizer Inc. |
Cyclic peptides as C5 a receptor antagonists
|
CA3032141A1
(en)
|
2016-07-29 |
2018-02-01 |
Vadim ALEXANDROV |
Compounds and compositions and uses thereof
|
MX2019000980A
(es)
|
2016-07-29 |
2019-07-04 |
Sunovion Pharmaceuticals Inc |
Compuestos y composiciones y usos de los mismos.
|
BR112019002538A2
(pt)
|
2016-08-11 |
2019-05-21 |
Ovid Therapeutics Inc. |
uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
|
MX2019001849A
(es)
|
2016-08-15 |
2019-05-09 |
Pfizer |
Inhibidores de cdk2/4/6 de piridopirimidinona.
|
US10532102B2
(en)
|
2016-08-19 |
2020-01-14 |
Foresee Pharmaceuticals Co., Ltd. |
Pharmaceutical composition and methods of uses
|
NZ751777A
(en)
*
|
2016-08-19 |
2020-08-28 |
Foresee Pharmaceuticals Co Ltd |
Pharmaceutical composition and methods of uses
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
US11266631B2
(en)
|
2016-10-11 |
2022-03-08 |
Purdue Pharmaceutical Products L.P. |
Hodgkin lymphoma therapy
|
JP2019535722A
(ja)
|
2016-11-18 |
2019-12-12 |
アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
修飾シクロデキストリン及び酸性化剤に基づくアミジン置換ベータ−ラクタム化合物の新規製剤、それらの製造及び抗菌医薬組成物としての使用
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
JP7125940B2
(ja)
|
2016-12-19 |
2022-08-25 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
|
CA3047010A1
(en)
|
2016-12-19 |
2018-06-28 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
PL3554553T3
(pl)
|
2016-12-19 |
2022-11-07 |
Sarepta Therapeutics, Inc. |
Koniugaty oligomerów z pominięciem egzonu w dystrofii mięśniowej
|
EP4252856A3
(de)
|
2016-12-20 |
2024-01-24 |
Oligomerix, Inc. |
Neuartige chinazolinone zur hemmung der bildung von tau-oligomeren und deren verfahren zur verwendung
|
AU2018208846A1
(en)
|
2017-01-20 |
2019-07-25 |
Pfizer Inc. |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
KR20190097242A
(ko)
|
2017-01-23 |
2019-08-20 |
화이자 인코포레이티드 |
Magl 억제제로서의 헤테로시클릭 스피로 화합물
|
EP3573979A1
(de)
|
2017-01-27 |
2019-12-04 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino)-methyl)benzyl)oxy)isoindolin-2-yl)piperidin-2,6-dion und isotopologe davon
|
IL268694B2
(en)
|
2017-02-16 |
2023-10-01 |
Sunovion Pharmaceuticals Inc |
Treatment of schizophrenia
|
DK3600312T3
(da)
|
2017-03-26 |
2023-07-31 |
Takeda Pharmaceuticals Co |
Piperidinyl- og piperazinylsubstituerede heteroaromatiske carboxamider som modulatorer af gpr6
|
US11767520B2
(en)
|
2017-04-20 |
2023-09-26 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
KR20190141244A
(ko)
*
|
2017-05-03 |
2019-12-23 |
사이덱스 파마슈티칼스, 인크. |
사이클로덱스트린 및 부설판을 함유하는 조성물
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
TWI799426B
(zh)
|
2017-06-22 |
2023-04-21 |
英商克拉德夫製藥有限公司 |
人類sting之小分子調節劑
|
KR20200020899A
(ko)
*
|
2017-06-30 |
2020-02-26 |
셀진 코포레이션 |
2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법
|
US10675296B2
(en)
|
2017-07-11 |
2020-06-09 |
Gilead Sciences, Inc. |
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
|
BR112020001433A2
(pt)
|
2017-08-02 |
2020-07-28 |
Sunovion Pharmaceuticals Inc. |
compostos de isocromano e usos dos mesmos
|
BR112020004047A2
(pt)
|
2017-08-30 |
2020-09-01 |
Beijing Xuanyi Pharmasciences Co., Ltd |
dinucleotídeos cíclicos como estimuladores de moduladores de genes interferon
|
EP3681879A1
(de)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals, Inc. |
Allosterische octahydrocyclopenta[c]pyrrolinhibitoren von shp2
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
US20200254002A1
(en)
|
2017-09-28 |
2020-08-13 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
EP3687577A1
(de)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Kombinationstherapien zur behandlung von muskeldystrophie
|
CA3089490A1
(en)
|
2018-01-29 |
2019-08-01 |
Phytoplant Research S.L |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
EP3759094A1
(de)
|
2018-03-01 |
2021-01-06 |
Takeda Pharmaceutical Company Limited |
Piperidinyl-3-(aryloxy)propanamide und -propanoate
|
US10538542B2
(en)
|
2018-03-15 |
2020-01-21 |
Pfizer Inc. |
Cyclopentane-based modulators of STING (stimulator of interferon genes)
|
KR20230152182A
(ko)
|
2018-04-26 |
2023-11-02 |
화이자 인코포레이티드 |
사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체
|
US10758629B2
(en)
|
2018-05-29 |
2020-09-01 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
JP2021525809A
(ja)
|
2018-05-30 |
2021-09-27 |
コンバート ファーマシューティカルズ エス.エー. |
プロドラッグおよびその医学的使用
|
BR112020024301A2
(pt)
|
2018-06-01 |
2021-02-23 |
Bayer Cropscience Lp |
composição fungicida estabilizada compreendendo ciclodextrina
|
EP4219717A3
(de)
|
2018-06-13 |
2023-12-20 |
Sarepta Therapeutics, Inc. |
Exon-skipping-oligomere für muskeldystrophie
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
JP2021531287A
(ja)
|
2018-07-19 |
2021-11-18 |
ファイザー・インク |
Magl阻害剤としての複素環式スピロ化合物
|
TW202020153A
(zh)
|
2018-07-27 |
2020-06-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
EP3886984A1
(de)
|
2018-11-29 |
2021-10-06 |
Pfizer Inc. |
Pyrazole als hämoglobinmodulatoren
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
AU2019397461A1
(en)
|
2018-12-13 |
2021-07-29 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
WO2020142716A1
(en)
|
2019-01-03 |
2020-07-09 |
Sens Research Foundation, Inc. |
Cyclodextrin dimers, compositions thereof, and uses thereof
|
WO2020141224A1
(en)
|
2019-01-04 |
2020-07-09 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
BR112021013019A2
(pt)
|
2019-01-23 |
2021-09-14 |
Pfizer Inc. |
Forma polimórfica de um sal de hidrato de monofosfato de um derivado de tetra-hidroisoquinolina conhecido
|
CN113330000A
(zh)
|
2019-01-31 |
2021-08-31 |
辉瑞公司 |
具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物
|
US11529357B2
(en)
|
2019-02-01 |
2022-12-20 |
H. Lundbeck A/S |
Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
|
EP3938045A1
(de)
|
2019-03-14 |
2022-01-19 |
Sunovion Pharmaceuticals Inc. |
Salze einer isochromanylverbindung und kristalline formen, verfahren zur herstellung, therapeutische verwendungen und pharmazeutische zusammensetzungen davon
|
AR118471A1
(es)
|
2019-03-22 |
2021-10-06 |
Takeda Pharmaceuticals Co |
Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2
|
SG11202108757XA
(en)
|
2019-03-28 |
2021-10-28 |
Sarepta Therapeutics Inc |
Methods for treating muscular dystrophy with casimersen
|
US20220193246A1
(en)
|
2019-04-18 |
2022-06-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
PE20220425A1
(es)
|
2019-04-29 |
2022-03-29 |
Solent Therapeutics Llc |
Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
|
US20220296633A1
(en)
|
2019-06-19 |
2022-09-22 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
TW202116734A
(zh)
|
2019-07-25 |
2021-05-01 |
印度商裘拉德製藥私人有限公司 |
乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑
|
CA3145923A1
(en)
|
2019-08-05 |
2021-02-11 |
David Czekai |
Ganaxolone for use in treatment of status epilepticus
|
CN114555127A
(zh)
|
2019-08-06 |
2022-05-27 |
L.E.A.F.控股集团公司 |
制备聚谷氨酸化抗叶酸剂的方法以及它们的组合物的用途
|
JP2022548602A
(ja)
|
2019-09-16 |
2022-11-21 |
武田薬品工業株式会社 |
アゾール縮合ピリダジン-3(2h)-オン誘導体
|
JP2022550297A
(ja)
|
2019-09-25 |
2022-12-01 |
ファイザー・インク |
Sting(インターフェロン遺伝子刺激因子)のヘテロ多環式モジュレーター
|
US20210145816A1
(en)
|
2019-11-15 |
2021-05-20 |
Cyclolab Cyclodextrin Research And Development Laboratory Ltd. |
Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
|
US20230023070A1
(en)
|
2019-12-02 |
2023-01-26 |
Celegene Corporation |
Therapy for the Treatment of Cancer
|
MX2022006014A
(es)
|
2019-12-06 |
2022-06-22 |
Marinus Pharmaceuticals Inc |
Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
|
KR20220141328A
(ko)
|
2020-02-12 |
2022-10-19 |
큐라데브 파마 프라이버트 리미티드 |
소분자 sting 길항제
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
WO2021220185A1
(en)
|
2020-05-01 |
2021-11-04 |
Pfizer Inc. |
Azalactam compounds as hpk1 inhibitors
|
PE20231375A1
(es)
|
2020-05-04 |
2023-09-07 |
Takeda Pharmaceuticals Co |
Derivados de n-(piperidin-4-il)benzamida de accion luminal
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
US20220306641A1
(en)
|
2021-03-18 |
2022-09-29 |
Pfizer Inc. |
Modulators of STING (Stimulator of Interferon Genes)
|
CA3213593A1
(en)
|
2021-03-31 |
2022-10-06 |
Sevenless Therapeutics Limited |
Sos1 inhibitors and ras inhibitors for use in the treatment of pain
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
EP4320121A2
(de)
|
2021-04-07 |
2024-02-14 |
LifeArc |
2,4-diaminopyrimidinderivate als ulk1/2-inhibitoren und deren verwendung
|
AU2022297733A1
(en)
|
2021-06-26 |
2024-01-04 |
Array Biopharma Inc. |
Her2 mutation inhibitors
|
WO2023015240A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Tricyclic fused pyrimidine compounds for use as her2 inhibitors
|
CA3228653A1
(en)
|
2021-08-11 |
2023-02-16 |
Monali BANERJEE |
Small molecule urea derivatives as sting antagonists
|
CA3228528A1
(en)
|
2021-08-11 |
2023-02-16 |
Monali BANERJEE |
Small molecule sting antagonists
|
EP4162933A1
(de)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Verbindung zur behandlung von nicht-alkoholischer fettlebererkrankung und verwandten erkrankungen
|
WO2023099072A1
(en)
|
2021-12-01 |
2023-06-08 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Compounds
|
WO2023178230A1
(en)
|
2022-03-17 |
2023-09-21 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
TW202345838A
(zh)
|
2022-04-07 |
2023-12-01 |
日商武田藥品工業股份有限公司 |
稠合噠嗪衍生物
|
US20240109915A1
(en)
|
2022-07-29 |
2024-04-04 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024073570A1
(en)
|
2022-09-28 |
2024-04-04 |
Altos Labs, Inc. |
Expression of regeneration factors in aged/senescent cells
|